Longitudinal assessment of neuropathy in type 1 diabetes using novel ophthalmic markers (LANDMark): Study design and baseline characteristics

Nicola Pritchard, Katie Edwards, Cirous Dehghani, Hassan Fadavi, Maria Jeziorska, Andrew Marshall, Ioannis N. Petropoulos, Georgios Ponirakis, Anthony W. Russell, Geoff P. Sampson, Ayda M. Shahidi, Sangeetha Srinivasan, Mitra Tavakoli, Dimitrios Vagenas, Rayaz A. Malik, Nathan Efron

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Aims: Corneal nerve morphology and corneal sensation threshold have recently been explored as potential surrogate markers for the evaluation of diabetic neuropathy. We present the baseline findings of the 'Longitudinal Assessment of Neuropathy in type 1 Diabetes using novel ophthalmic Markers'(LANDMark) study. Methods: The LANDMark study is a 4-year, two-site, natural history study of three participant groups: type 1 diabetes with neuropathy (T1W), type 1 diabetes without neuropathy (T1WO) and control participants without diabetes or neuropathy. All participants undergo a detailed annual assessment of neuropathy including corneal nerve parameters measured using corneal confocal microscopy and corneal sensitivity measured using non-contact corneal aesthesiometry. Results: 76 T1W, 166 T1WO and 154 control participants were enrolled into the study. Corneal sensation threshold was significantly higher (i.e., sensitivity was lower) in T1W (1.0±1.1mbars) than T1WO (0.7±0.7mbars) and controls (0.6±0.4mbars) (p<0.001), with no difference between T1WO and controls. Corneal nerve fibre length was lower in T1W (14.0±6.4mm/mm2) compared to T1WO (19.1±5.8mm/mm2) and controls (23.2±6.3mm/mm2) (p<0.001). Corneal nerve fibre length was lower in T1WO compared to controls. Conclusions: The LANDMark baseline findings confirm a reduction in corneal sensitivity only in Type 1 patients with neuropathy. However, corneal nerve fibre length is reduced in Type 1 patients without neuropathy with an even greater deficit in Type 1 patients with neuropathy.

Original languageEnglish
Pages (from-to)248-256
Number of pages9
JournalDiabetes Research and Clinical Practice
Volume104
Issue number2
DOIs
Publication statusPublished - May 2014
Externally publishedYes

Fingerprint Dive into the research topics of 'Longitudinal assessment of neuropathy in type 1 diabetes using novel ophthalmic markers (LANDMark): Study design and baseline characteristics'. Together they form a unique fingerprint.

  • Cite this

    Pritchard, N., Edwards, K., Dehghani, C., Fadavi, H., Jeziorska, M., Marshall, A., Petropoulos, I. N., Ponirakis, G., Russell, A. W., Sampson, G. P., Shahidi, A. M., Srinivasan, S., Tavakoli, M., Vagenas, D., Malik, R. A., & Efron, N. (2014). Longitudinal assessment of neuropathy in type 1 diabetes using novel ophthalmic markers (LANDMark): Study design and baseline characteristics. Diabetes Research and Clinical Practice, 104(2), 248-256. https://doi.org/10.1016/j.diabres.2014.02.011